Best practice in primary care pathology: Review 12

Journal of Clinical Pathology

Volumn 63, Issue 4, 2010, Pages 330-336

  Smellie, W S A ^a   McNulty, C A M ^b   Collinson, P O ^c   Shaw, N ^d   Bowley, R ^d  

^a BISHOP AUCKLAND GENERAL HOSPITAL   (United Kingdom)

^b GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d All Saints Business Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BRAIN NATRIURETIC PEPTIDE; CARBAMAZEPINE; CHLORHEXIDINE GLUCONATE; CLINDAMYCIN; CLONAZEPAM; DOXYCYCLINE; ETHOSUXIMIDE; ETIRACETAM; FUSIDATE SODIUM; GABAPENTIN; LAMOTRIGINE; LINEZOLID; METHYLPHENOBARBITAL; METRONIDAZOLE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; POVIDONE IODINE; PRIMIDONE; PSEUDOMONIC ACID; RIFAMPICIN; TIAGABINE; TOPIRAMATE; TRICLOSAN; TRIMETHOPRIM; VALPROIC ACID; VANCOMYCIN; VIGABATRIN;

CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE; CONSENSUS; DRUG BLOOD LEVEL; DRUG MONITORING; ECHOCARDIOGRAPHY; EMBASE; EVIDENCE BASED MEDICINE; FECES ANALYSIS; HEALTH CARE POLICY; HEART FAILURE; HOSPITAL DISCHARGE; HUMAN; INFECTIOUS DIARRHEA; LABORATORY TEST; MEDICAL LITERATURE; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SCREENING; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW;

ANTICONVULSANTS; DIARRHEA; DRUG MONITORING; HUMANS; MASS SCREENING; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NATRIURETIC PEPTIDE, BRAIN; PRIMARY HEALTH CARE; SPECIMEN HANDLING; STAPHYLOCOCCAL INFECTIONS;

EID: 77950453659     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.073510     Document Type: Review

References (49)

1. Glauser TA, Pippenger CE. Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy. Epilepsia 2000;41(Suppl 8):S6-15. (Abstract).
2. NICE. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. National Institute of Health and Clinical Excellence 2004. www.nice.org.uk (accessed 20 Dec2007). (Free Full-text).
3. SIGN. Diagnosis and management of epilepsy in adults: a national clinical guideline. Scottish Intercollegiate Guidelines Network. 2003. www.sign.ac.uk (accessed 20 Dec 2007). (Free Full-text).
4. SIGN. Diagnosis and management of epilepsies in children and young people: a national clinical guideline. Scottish intercollegiate guidelines network. 2005. www.sign.ac.uk (accessed 20 Dec 2007). (Free Full-text).
5. Jannuzzi G, Cian P, Fattore C, et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. Epilepsia 2000;41920:222-230 (Pubitemid 30097069)
6. Tomson T, Dahl ML, Kimland E. Therapeutic monitoring of antiepileptic drugs for epilepsy (Cochrane Review). Cochrane Database Syst Rev 2007 (Issue 2). www.thecochranelibrary.com (accessed 2 Jan 2008). (Free Full-text).
7. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clinical Pharmacokinetics 2007;46:209-219 (Pubitemid 46425647)
8. Adab N. Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: Is it useful? CNS Drugs 2006;20:791-800.
9. Vajda EJE, Merory J, Bladin PE. Fluctuation of plasma Phenytoin levels on single dose and twice daily dosage regimens. Proc Assoc Nurol 1975;12:61-64
10. Eadie MJ. Therapeutic drug monitoring - antiepileptic drugs. British Journal of Clinical Pharmacology 2001;46:185-193
11. Health Protection agency. Association of medical microbiologists. infectious diarrhoea, the role of microbiological examination of faeces. Quick reference guide for primary care.
12. Al-Abri SS, Beeching NJ, Nye FJ. Traveller's diarrhoea. Lancet Infect Dis 2005;5:349-360
13. Thielman NM, Guerrant RL. Acute infectious diarrhoea. N Eng J Med 2004;350:38-47.
14. Wheeler JG, Sethi D, Cowden JM, et al. Roderick PJ on behalf of the Infectious Intestinal Disease Study Executive. Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. BMJ 1999;318:1046-1050
15. Geurrant RK, Gilder TV, Steiner TS, et al. Practice guidelines for the management of infectious diarrhoea. Clin Infect Dis 2001;32:331-351 (Pubitemid 32173618)
16. Katz DE, Taylor DN. Parasitic infections of the gastrointestinal tract. Gastroenterology Clinics of North America 2001;30:797-815.
17. Van Gool T, Weijts R, Lommerse E, et al. Triple faeces test: an effective tool for detection of intestinal parasites in routine clinical practice. Eur J Clin Microbiol Infect Dis 2003;22:284-290 (Pubitemid 36760450)
18. Ternhag A, Asikainen T, Giesecke J, et al. A meta-analysis on the effect of antibiotic treatment on duration of symptoms caused by infection with campylobacter species. Clin Infect Dis 2007;44:696-700. (Pubitemid 46272980)
19. Health Protection Agency and Association of Medical Microbiologists. Meticillin resistant Staphylococcus aureus (MRSA) screening and suppression quick reference guide for primary care.
20. Coia JE, Duckworth GJ, Edwards DI, et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 2006;63S:S1-44.
21. Maudsley J, Stone SP, Kibbler CC, et al. The community prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in older people living in their own homes: implications for treatment, screening and surveillance in the UK. J Hosp Infect 2004;57:258-262 (Pubitemid 38967337)
22. Barr B, Wilcox M, Tompkins D, et al. A methicillin resistant Staphylococcus aureus (MRSA) prevalence survey, in Leeds care homes. Infect Control Hosp Epidemiol 2007. In press.
23. Health Protection Agency. Trends in antimicrobial resistance in England and Wales, 2004-2005. London: Health Protection Agency, 2006.
24. Gemmell CG, Edwards DI, Fraise AP, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006;57:589-608.
25. Harbarth S, Liassine N, Dharan S, et al. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000;31:1380-1385
26. Department of Health. Screening for meticillin-resistant Staphylococcus aureus (MRSA) colonisation. A strategy for NHS trusts: summary of best practice 2006. http://www.dh.gov.uk/reducingmrsa.
27. Kampf G, Kramer A. Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs. Clin Microbiol Rev 2004;17:863-893 (Pubitemid 39372521)
28. University College London Hospital. MRSA information for primary care. London: University College London Hospital 2006.
29. Anon. Methicillin resistant Staphylococcus aureus (MRSA). Lothian Health Guidelines 2000.
30. Anon. Guidelines for the control of methicillin-resistant Staphylococcus aureus in New Zealand. New Zealand: Ministry of Health, 2002. http://www.moh.govt.nz/publications/guidelines.
31. Eriksen NHR, Espersen F, Rosdahld VT, et al. Evaluation of methods for the detection of nasal carriage of Staphylococcus aureus. APMIS 1994;102:407-412 (Pubitemid 24266217)
32. Loeb M, Main C, Walker-Dilks C, et al. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization (Review). Cochrane Database Syst Rev 2004; (4):CD003340.
33. NICE Clinical Guideline CG5. Chronic heart failure 2003. London: Royal College of Physicians.
34. Dickstein K, Cohen-Solal A, Filippatos G, et al. Acute and chronic heart failure (diagnosis and treatment)European society of cardiology clinical practice guidelines. http://www.escardio.org/guidelines-surveys/esc-guidelines/ Pages/acute-chronic-heart-failure.aspx.
35. Craig J, Bradbury I, Cummins E, et al. The use of B- with suspected heart failure. Health Technology Assessment Report 6 5 A.D.
36. Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of the implications of different diagnostic strategies in primary care. Health Technology Assessment Report 2009;13:1-232. http://www.hta.ac.uk/execsumm/ summ1332.shtml (accessed Aug 2009).
37. Rosenberg J, Schou M, Gustafsson F, et al. Prognostic threshold levels of NT-proBNP testing in primary care. Eur Heart J 2009;30:66-73.
38. Lim TK, Collinson PO, Celik E, et al. Value of primary care electrocardiography for the prediction of left ventricular systolic dysfunction in patients with suspected heart failure. Int J Cardiol 2006.
39. Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-675 (Pubitemid 40239214)
40. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-663 (Pubitemid 38364624)
41. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol 2007;49:1733-1739 (Pubitemid 46589928)
42. Smellie WSA, Forth J, Coleman J J, et al. Best Practice in primary care pathology. Review 6. J. Clin Pathol 2007;60:225-234 (Pubitemid 46447735)
43. Smellie WSA, Wilson D, Finnegan DI, et al. Best practice in pathology. Methodology for constructing guidance. J Clin Path 2005;58:249-253 (Pubitemid 40380317)
44. Smellie WSA, Vanderpump MPJ, Fraser WD, et al. Best practice in primary care pathology. Review 11. J Clin Pathol 2008;61-65
45. NHS Confederation. Quality and outcomes framework. Guidance for GMS contract 2009/10. NHS Confederation. http://www.nhsemployers.org/ PayAndContracts/GeneralMedicalServicesContract/QOF/Pages/ QualityOutcomesFramework.aspx (accessed Oct 2006).
46. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167
47. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of NT-proBNP Study. Eur Heart J 2006;27:330-337 (Pubitemid 43100029)
48. Fuat A, Murphy JJ, Hungin AP, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006;56:327-333
49. Hildebrandt P, Collinson PO. Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. Am J Cardiol 2008;101:25-28